Halozyme Therapeutics Inc (HALO)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Operating income | US$ in thousands | 551,475 | 337,574 | 267,531 | 275,902 | 144,255 |
| Total assets | US$ in thousands | 2,063,480 | 1,733,270 | 1,841,510 | 1,104,430 | 579,924 |
| Operating ROA | 26.73% | 19.48% | 14.53% | 24.98% | 24.87% |
December 31, 2024 calculation
Operating ROA = Operating income ÷ Total assets
= $551,475K ÷ $2,063,480K
= 26.73%
Halozyme Therapeutics Inc's operating return on assets (Operating ROA) has shown fluctuations over the years based on the provided data. The ratio increased from 24.87% in 2020 to 24.98% in 2021, indicating a slight improvement in the company's efficiency in generating operating income from its assets. However, there was a significant drop in Operating ROA in 2022 to 14.53%, suggesting a potential decrease in the company's operational efficiency or profitability during that period.
Subsequently, the Operating ROA rebounded in 2023 to 19.48%, indicating a recovery in the company's ability to generate operating income relative to its asset base. Finally, the ratio surged to 26.73% in 2024, reaching its highest point in the provided data set. This increase suggests that the company was able to significantly enhance its operational performance and profitability compared to the previous years.
In summary, Halozyme Therapeutics Inc's Operating ROA has shown variability over the years, with some fluctuations indicating potential changes in the company's operational efficiency and profitability. It is essential for stakeholders to monitor these ratios to assess the company's performance and sustainability.
Peer comparison
Dec 31, 2024